All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 25, 2021
Home » Blogs » BioWorld Perspectives » Evolution: Survival of the Fittest, and Some Others

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

Evolution: Survival of the Fittest, and Some Others

March 14, 2013
By Anette Breindl
No Comments

If you believe in evolution at all, you probably think of it as a good thing for the evolving organism, enabling it to keep up with its environment as that environment changes. I sure do.

Of course, we realize that bad mutations can happen to good cells. The idea that most mutations are actually bad for an organism is a basic tenet of evolutionary theory. But then, the theory goes, the bad mutations get weeded out because their owners are now at a disadvantage.

By and large, of course, the reason we think of evolution like that is because it’s true. But every now and then, I come across papers that bring home the fact that evolution is also very complex, and not necessarily a one-way street toward the better.

Two such papers recently have made this point. One showed that evolution can let cells permanently acquire things that are bad for them – in this case, mutations that slow their growth. The other, while it does not deal directly with evolution, suggests that processes such as inflammation can evolve into different directions for reasons that remain mysterious to us.

The first paper, published a few weeks back, deals with so-called passenger mutations, and shows that instead of being neutral, they in fact put a drag on cancer cell growth.

In their work, the authors showed what senior author Leonid Mirny called a "counterintuitive” truth: that “in an evolutionary process, you can accumulate mutations that are bad for you.” That is exactly what happens to cancer cells, where driver mutations that give the cells a growth advantage can take passenger mutations that give them a disadvantage along for the ride.

The second paper does not deal directly with evolution at all. Instead, its authors showed that the inflammatory processes that happen in mice are very different from those that happen in humans.

You can find the details here and here. But basically, it appears that humans have a much stronger inflammatory response to bacteria.

Why? Because they evolved that way. Well, yeah, but why?

“The assumption is that there has to be some advantage to the way we do it,” co-first author Shaw Warren told BioWorld Today when his paper came out. “But the fact of the matter is that no one has been able to make a convincing case for what that advantage might be.”

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Seniors with wooden puzzle

    Cassava’s simufilam improves AD patients’ cognition, behavior

    BioWorld
    When Cassava Sciences Inc.’s president and CEO, Remi Barbier, opened up the interim analysis of the company’s open-label study for Alzheimer’s disease candidate...
  • Vaxart COVID-19 vaccine tablets

    Vaxart shares shaken despite apparently positive early data for oral COVID-19 vaccine

    BioWorld
    Vaxart Inc. investors who stuck by company shares Feb. 3 had to swallow a bitter pill – watching shares of the oral vaccine developer (NASDAQ:VXRT) fall 57.8% to...
  • IPO money

    Lucira Health launches $153M IPO

    BioWorld MedTech
    Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 25.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing